NASDAQ:QCLS

Mymd Pharmaceuticals (QCLS) Stock Price, News & Analysis

Mymd Pharmaceuticals logo
$0.31 -0.03 (-8.29%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-0.10%)
As of 11/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Mymd Pharmaceuticals Stock (NASDAQ:QCLS)

Advanced

Key Stats

Today's Range
$0.30
▼
$0.33
50-Day Range
$0.31
▼
$1.71
52-Week Range
$0.28
▼
$8.17
Volume
374,222 shs
Average Volume
395,088 shs
Market Capitalization
$2.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

MyMD Pharmaceuticals is a clinical-stage biopharmaceutical company that has focused on developing treatments for inflammatory and age-related conditions. Its work has centered on drug candidates intended to address diseases for which existing treatment options may be limited.

The company’s lead candidate, MYMD-1, is an investigational oral therapy designed to regulate inflammatory processes and the immune system. MyMD has studied its potential application across a range of chronic conditions; it is not an approved medicine.

MyMD has also advanced Supera-CBD, a synthetic cannabinoid candidate investigated for potential therapeutic uses. The company’s activities have been focused on drug research and development rather than marketing an established portfolio of commercial medicines.

AI Generated. May Contain Errors.

Mymd Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
15th Percentile Overall Score

QCLS MarketRank™: 
0.758904109585 of 5 stars

Mymd Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mymd Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Mymd Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Mymd Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mymd Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mymd Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mymd Pharmaceuticals has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.19% of the float of Mymd Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Mymd Pharmaceuticals has a short interest ratio ("days to cover") of 6.16.
  • Change versus previous month

    Short interest in Mymd Pharmaceuticals has recently decreased by 8.93%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mymd Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Mymd Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Mymd Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Mymd Pharmaceuticals this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Mymd Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mymd Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.86% of the stock of Mymd Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    9.64% of the stock of Mymd Pharmaceuticals is held by institutions.

  • Read more about Mymd Pharmaceuticals' insider trading history.
Receive QCLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mymd Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QCLS Stock News Headlines

432 miles southeast of Washington, DC…
Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip maker for nearly four decades, including AMD, Intel, NVIDIA, Samsung and Taiwan Semiconductor. Washington is set to declare it a national strategic resource and ban its export. Apple, NVIDIA and Amazon have committed over $2 trillion, and Morgan Stanley estimates a $10 trillion economic boom. One small U.S. mining company sits at the center of it.tc pixel
See More Headlines

QCLS Stock Analysis - Frequently Asked Questions

Mymd Pharmaceuticals' stock was trading at $4.33 on May 15, 2026. Since then, QCLS stock has decreased by 92.9% and is now trading at $0.3063.

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.14) EPS for the quarter.

Shares of QCLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Technology Hardware, Storage & Peripherals
Sub-Industry
Technology Hardware, Storage & Peripherals
Current Symbol
NASDAQ:QCLS
CIK
1321834
Employees
2
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.63 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-75.85%
Return on Assets
-43.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.29
Quick Ratio
3.29

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.19 per share
Price / Book
0.06

Miscellaneous

Outstanding Shares
8,190,000
Free Float
8,120,000
Market Cap
$2.51 million
Optionable
N/A
Beta
2.21
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:QCLS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners